ALM 201

Drug Profile

ALM 201

Alternative Names: ALM-201; FKBPL; FKBPL-derived anticancer peptides; Peptide anti-angiogenic compounds - Queens University Belfast/Almac Discovery

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almac Discovery; Queens University Belfast
  • Developer Almac Discovery
  • Class Antineoplastics; Peptide fragments
  • Mechanism of Action Angiogenesis inhibitors; CD44 antigen modulators; Cell movement inhibitors; Immunophilin modulators; Microtubule protein modulators; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • No development reported Ovarian cancer; Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Ovarian-cancer in United Kingdom (SC, Injection)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (SC, Injection)
  • 08 Sep 2017 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top